Faculty Opinions recommendation of Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study.

BackgroundIn individual studies and limited meta-analyses venlafaxine has been reported to be more effective than comparator antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs).AimsTo perform a systematic review of all such studies.MethodWe conducted a systematic review of double-blind, randomised trials comparing venlafaxine with alternative antidepressants in the treatment of depression. The primary outcome was the difference in final depression rating scale value, expressed as a standardised effect size. Secondary outcomes were response rate, remission rate and tolerability.ResultsA total of 32 randomised trials were included. Venlafaxine was more effective than other antidepressants (standardised effect size was −0.14, 95% Cl −0.07 to −0.22). A similar significant advantage was found against SSRIs (20 studies) but nottricyclic antidepressants (7 studies).ConclusionsVenlafaxine has greater efficacy than SSRIs although there is uncertainty in comparison with other antidepressants. Further studies are required to determine the clinical importance of this finding.

Download Full-text

Quetiapine augmentation to serotonin reuptake inhibitors for patients with obsessive compulsive disorder: a double-blind, placebo-controlled study

http://isrctn.org/> ◽

10.1186/isrctn40781401 ◽

2013 ◽

Author(s):

Nienke C C Vulink

Keyword(s):

Obsessive Compulsive Disorder ◽

Serotonin Reuptake ◽

Serotonin Reuptake Inhibitors ◽

Controlled Study ◽

Obsessive Compulsive ◽

Double Blind ◽

Double Blind Placebo ◽

Compulsive Disorder

Download Full-text

Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder

The World Journal of Biological Psychiatry ◽

10.1080/15622970701432528 ◽

2007 ◽

pp. 1-8 ◽

Cited By ~ 2

Author(s):

George I. Papakostas ◽

Dana Charles ◽

Maurizio Fava

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Serotonin Reuptake ◽

Selective Serotonin Reuptake Inhibitors ◽

Meta Analysis ◽

Serotonin Reuptake Inhibitors ◽

Dose Finding ◽

Major Depressive ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(98)00694-9 ◽

1999 ◽

Vol 33 (5) ◽

pp. 1227-1230 ◽

Cited By ~ 205

Author(s):

Enrico Di Girolamo ◽

Cesare Di Iorio ◽

Panfilo Sabatini ◽

Luigi Leonzio ◽

Carmela Barbone ◽

...

Keyword(s):

Selective Serotonin Reuptake Inhibitor ◽

Reuptake Inhibitor ◽

Serotonin Reuptake ◽

Vasovagal Syncope ◽

Selective Serotonin ◽

Controlled Study ◽

Serotonin Reuptake Inhibitor ◽

Double Blind ◽

Double Blind Placebo ◽

Paroxetine Hydrochloride

Download Full-text

Differential Impact of Selective Serotonin Reuptake Inhibitors on Platelet Response to Clopidogrel: A Randomized, Double-Blind, Crossover Trial

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ◽

10.1002/phar.1542 ◽

2015 ◽

Vol 35 (2) ◽

pp. 140-147 ◽

Cited By ~ 7

Author(s):

Bruria HirshRokach ◽

Galia Spectre ◽

Ela Shai ◽

Amit Lotan ◽

Amit Ritter ◽

...

Keyword(s):

Serotonin Reuptake ◽

Selective Serotonin Reuptake Inhibitors ◽

Crossover Trial ◽

Serotonin Reuptake Inhibitors ◽

Selective Serotonin ◽

Platelet Response ◽

Differential Impact ◽

Double Blind

Download Full-text

Efficacy of selective serotonin reuptake inhibitors and adverse events: Meta-regression and mediation analysis of placebo-controlled trials

The British Journal of Psychiatry ◽

10.1192/bjp.bp.114.150136 ◽

2016 ◽

Vol 208 (2) ◽

pp. 114-119 ◽

Cited By ~ 23

Author(s):

Michael Barth ◽

Levente Kriston ◽

Swaantje Klostermann ◽

Corrado Barbui ◽

Andrea Cipriani ◽

...

Keyword(s):

Adverse Events ◽

Serotonin Reuptake ◽

Selective Serotonin Reuptake Inhibitors ◽

Serotonin Reuptake Inhibitors ◽

Response To Treatment ◽

Selective Serotonin ◽

Controlled Trials ◽

Regression Analyses ◽

Double Blind ◽

Meta Regression

BackgroundIt has been suggested that the efficacy of antidepressants has been overestimated in clinical trials owing to unblinding of drug treatments by adverse events.AimsTo investigate the association between adverse events and the efficacy of selective serotonin reuptake inhibitors (SSRIs).MethodThe literature was searched to identify randomised, double-blind, placebo-controlled trials of SSRIs in the treatment of major depression. Efficacy outcomes were response to treatment and change in depressive symptoms. Reporting of adverse events was used as an indicator of tolerability. Random effects meta-analyses were used to calculate pooled estimates. Meta-regression analyses were performed to investigate the association between adverse events and efficacy. Potential mediation was investigated with the Baron & Kenny approach.ResultsA total of 68 trials (n = 17 646) were included in the analyses. In meta-analysis SSRIs were superior to placebo in terms of efficacy (odds ratio, OR = 1.62, 95% CI 1.51–1.72). More patients allocated to SSRIs reported adverse events than did patients receiving placebo (OR = 1.73, 95% CI 1.58–1.89). Meta-regression analyses did not find an association between adverse events and efficacy (P = 0.439). There was no indication of adverse events mediating the effect of SSRI treatment.ConclusionsOur results do not support, but also do not unequivocally disprove, the hypothesis that adverse events lead to an overestimation of the effect of SSRIs over placebo.

Download Full-text